| 1 |
中华医学会外科学分会乳腺外科学组. 中国早期乳腺癌前哨淋巴结活检手术临床实践指南(2022版) [J]. 中国实用外科杂志, 2022, 42(2): 137-145.
|
| 2 |
Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial [J]. JAMA, 2013, 310(14): 1455-1461.
|
| 3 |
Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study [J]. Lancet Oncol, 2013, 14(7): 609-618.
|
| 4 |
Hu Z, Cheng X, Li J, et al. Preliminary study of real-time three-dimensional contrast-enhanced ultrasound of sentinel lymph nodes in breast cancer [J]. Eur Radiol, 2020, 30(3): 1426-1435.
|
| 5 |
Amin MB, Edge SB, Greene FL, et al. AJCC Cancer Staging Manual [M]. 8th ed. New York: Springer, 2016: 589-628.
|
| 6 |
Xie F, Zhang D, Cheng L, et al. Intradermal microbubbles and contrast-enhanced ultrasound (CEUS) is a feasible approach for sentinel lymph node identification in early-stage breast cancer [J]. World J Surg Oncol, 2015, 13: 319.
|
| 7 |
Hammond ME, Hayes DF, Wolff AC, et al. American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer [J]. J Oncol Pract, 2010, 6(4): 195-197.
|
| 8 |
Wolff AC, Hammond M, Allison KH, et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update [J]. J Clin Oncol, 2018, 36(20): 2105-2122.
|
| 9 |
Elston CW, Ellis IO. Pathological prognostic factors in breast cancer.I.The value of histological grade in breast cancer:experience from a large study with long-term follow-up [J]. Histopathology, 2002, 41(3A): 154-161.
|
| 10 |
Ogston KN, Miller ID, Payne S, et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival [J]. Breast, 2003, 12(5): 320-327.
|
| 11 |
Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis [J]. Lancet, 2014, 384(9938): 164-172.
|
| 12 |
Giuliano AE, Kirgan DM, Guenther JM, et al. Lymphatic mapping and sentinel lymphadenectomy for breast cancer [J]. Ann Surg, 1994, 220(3): 391-398; discussion 398-401.
|
| 13 |
Veronesi U, Paganelli G, Viale G, et al. Sentinel-lymph-node biopsy as a staging procedure in breast cancer: update of a randomised controlled study [J]. Lancet Oncol, 2006, 7(12): 983-990.
|
| 14 |
Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial [J]. Lancet Oncol, 2010, 11(10): 927-933.
|
| 15 |
Li J, Lu M, Cheng X, et al. How pre-operative sentinel lymph node contrast-enhanced ultrasound helps intra-operative sentinel lymph node biopsy in breast cancer: initial experience [J]. Ultrasound Med Biol, 2019, 45(8): 1865-1873.
|
| 16 |
Mougalian SS, Hernandez M, Lei X, et al. Ten-year outcomes of patients with breast cancer with cytologically confirmed axillary lymph node metastases and pathologic complete response after primary systemic chemotherapy [J]. JAMA Oncol, 2016, 2(4): 508-516.
|
| 17 |
甘良雨, 辛灵, 程元甲, 等. 乳腺癌腋窝淋巴结转移患者新辅助化疗后腋窝病理完全缓解的相关因素分析 [J].中华临床医师杂志(电子版), 2021, 15(10): 768-773.
|
| 18 |
Boughey JC, McCall LM, Ballman KV, et al. Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial [J]. Ann Surg, 2014, 260(4): 608-614; discussion 614-616.
|
| 19 |
Mamtani A, Barrio AV, King TA, et al. How often does neoadjuvant chemotherapy avoid axillary dissection in patients with histologically confirmed nodal metastases? Results of a prospective study [J]. Ann Surg Oncol, 2016, 23(11): 3467-3474.
|
| 20 |
Montagna G, Mamtani A, Knezevic A, et al. Selecting node-positive patients for axillary downstaging with neoadjuvant chemotherapy [J]. Ann Surg Oncol, 2020, 27(11): 4515-4522.
|